ClinicalTrials.gg
RecruitingNCT06110949TROMBODOMUpdated May 8, 2024

Thromboembolic Risk Assessment in Patients Admitted With Acute Medical Diseases to Conventional and At Home Hospitalization

An observational study in Thromboprophylaxis, Thromboembolism, Venous and Atrial Fibrillation, sponsored by Universidad Pública de Navarra. Recruiting at 1 site in Spain. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-05-08.

Sponsored by Universidad Pública de Navarra · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Jan 2025, 1 year 9 months ago, but the record still lists the study as recruiting.
  • Started Mar 2023; still recruiting 3 years 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
1,953
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 52 studies in Venous Thromboembolism with a site in Spain — 9 open to participants now, 9 under way, none of them phase 3. Venous Thromboembolism · Spain.

Planned enrollment
7th of 16
1,953 · median 1,225
Started
2023
the only one that year
Observational
17 of 52
9 open now
Registered
50th of 52
by date

Among the 52 studies in Venous Thromboembolism with a site in Spain, this one is the 7th largest by planned enrollment of the 16 observational ones that give a count, is the only one that started in 2023, is one of 17 observational ones, and was the 50th registered.

Venous Thromboembolism

714 studies on the registry are indexed under Venous Thromboembolism; 148 are open to participants now.

Browse Venous Thromboembolism studies →

Open to participants now

9 of the 52 studies in Venous Thromboembolism with a site in Spain are open now. Recruiting first, the newest first:

3 more — sign in →

All 9 open studies →

A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →

Who these studies take

Of the 114 Venous Thromboembolism studies recruiting now, 91 (80%) set no upper age limit and 13 (11%) stop at 75 or younger; 9 take children under 18; 10 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 52 studies in Venous Thromboembolism with a site in Spain, or all of them as a file.
02

Study summary

The thromboembolic disease is a common complication of patients admitted to conventional hospitalization units. To prevent such complications, thromboprophylaxis is indicated in high-risk patients identified with validated risk-assessment models such as Padua score and IMPROVE-VTE score. However, the relation between thromboembolic disease and inpatients is yet to be demonstrated in new clinical settings such as at home hospitalization units. Moreover, patient immobilization is key in the pathogenesis of thromboembolic complications: therefore, it is crucial to collect raw data of patient mobility during admission.

The goal of this observational study is to compare the thromboembolic risk of patients admitted with acute medical diseases to at home hospitalization units with conventional hospitalization units.

The main questions it aims to answer are:

  • Is the estimated thromboembolic risk of patients admitted with acute medical diseases to at home hospitalization units similar to those admitted to conventional hospitalization units?
  • Are the risk-assessment models used to predict thromboembolic risk of patients admitted with acute medical diseases to conventional hospitalization units (Padua and IMPROVE-VTE score) valid in at home hospitalization patients?

Participants admitted with acute medical diseases to either a conventional hospitalization unit or at home hospitalization units will be included in a prospective registry in order to investigate the 90 days incidence of thromboembolic disease. A cohort of such patients will be controlled with triaxial accelerometer in order to collect raw data regarding patient mobility during admission.

Read the detailed description

1953 patients will be recruited (1700 in at home hospitalization units and 253 in conventional hospitalization units). All patients must accept and sign the informed consent. After being admitted to the study, patients will be included in the prospective registry with baseline evaluation of basic clinical data, including risk-assessment models (Padua and IMPROVE-VTE scores), examination, ECG, self-assessed mobility, and biochemistry markers. Triaxial accelerometers will also record mobility and sleep time of 135 patients from conventional hospitalization units and 135 patients from at home hospitalization units, from which physical activity questionnaires (International Physical Activity Questionnaire (IPAQ), The Spanish Short Version of the Minnesota Leisure Time Physical Activity Questionnaire (VREM)), handgrip strength, 30-second sit-to-stand test, the Short Physical Performance Battery (SPPB), the Spanish Version of 5-level European Quality of Life-5 Dimensions (5-level EQ-5D), Fried frailty criteria and Lobo's cognitive mini-examination will also be obtained. All 1953 patients will be followed for 90 days after discharge to assess thromboembolic disease incidence (pulmonary embolism, deep venous thrombosis, and atrial fibrillation), major and clinically relevant non-major bleedings (according to International Society on Thrombosis and Haemostasis Standards) and death.

03

Conditions studied

  • Thromboprophylaxis
  • Thromboembolism, Venous
  • Atrial Fibrillation
  • Physical Inactivity
  • Hospital at Home

Keywords

  • Thromboprophylaxis
  • Thromboembolism
  • Atrial Fibrillation
  • Accelerometry
  • Hospital at Home
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients admitted with acute medical diseases (non-surgical setting) to either a conventional hospitalization unit or at home hospitalization units, whenever able to understand the study protocol and sign the informed consent form, will be offered to participate in this study. In patients' best interests, those with end-of-life disease, receiving palliative care or with an expected life survival inferior to 3 months will not be included. To correctly evaluate the study outcomes, patients receiving therapeutic doses of any anticoagulant drug, those with active diagnosis of thromboembolic disease or prior diagnosis of atrial fibrillation will not be included. Finally, this study excludes pregnant or breast-feeding people and patients with active or recent SARS-CoV2 infection, due to well recognized differences in the pathophysiology of thromboembolic disease in such populations.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥ 18 years
  • Patients admitted with acute medical diseases to either a conventional hospitalization unit or at home hospitalization units
  • Capable and willing to provide an

Exclusion criteria

Exclusion Criteria:

  • End of life disease, palliative care or with an expected survival inferior to 3 months
  • Patients receiving therapeutic doses of any anticoagulant drug
  • Active diagnosis of thromboembolic disease
  • Prior diagnosis of atrial fibrillation
  • Pregnancy or breast-feeding.
  • SARS-CoV-2 diagnosed using real-time reverse transcriptase polymerase chain reaction (PCR) tests or positive for SARS-CoV-2 virus antigen \<90 days before randomization.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
1,953 participants (estimated)
Target follow-up
90 Days
Patient registry
Yes

Groups and cohorts

  • At home hospitalization cohort

    Participants admitted with acute medical diseases to at home hospitalization units will be included in a prospective registry in order to investigate the 90 days incidence of thromboembolic disease. A group of such patients will be controlled with triaxial accelerometer in order to collect raw data regarding patient mobility during admission.

    Device: Triaxial accelerometry

  • Conventional hospitalization cohort

    Participants admitted with acute medical diseases to a conventional hospitalization unit will be included in a prospective registry in order to investigate the 90 days incidence of thromboembolic disease. A group of such patients will be controlled with triaxial accelerometer in order to collect raw data regarding patient mobility during admission.

    Device: Triaxial accelerometry

Interventions

  • DeviceTriaxial accelerometry

    A group of patients will be controlled with triaxial accelerometer (GENEActiv watch) on left wrist at a sampling rate of 85,70 Hz to measure movement in the x, y, and z direction, in order to collect raw data regarding patient mobility (duration of sleep, the time spent in sedentary attitudes and the amount of light, moderate and vigorous physical activity) during the admission (from the admission day to discharge).

06

What researchers measure

Primary outcomes

  1. Estimated thrombotic risk at admission measured with Padua score

    Estimated thrombotic risk of patients admitted with acute medical diseases to at home hospitalization units and conventional hospitalization units will be measured with Padua score (high or low risk). "Padua" score is a risk assessment model that scores from 0 to 20, with a score of 4 or higher identifying patients at "high risk" of thromboembolic disease.

    Time frame: Within 3 months after hospitalization

  2. Estimated thrombotic risk at admission measured with IMPROVE-VTE score

    Estimated thrombotic risk of patients admitted with acute medical diseases to at home hospitalization units and conventional hospitalization units will be measured with IMPROVE-VTE score (high or low risk). "IMPROVE-VTE" score is a risk assessment model that scores from 0 to 12, with a score of 2 or higher identifying patients at "high risk" of thromboembolic disease.

    Time frame: Within 3 months after hospitalization

  3. Estimated hemorrhagic risk at admission

    Estimated hemorrhagic risk of patients admitted with acute medical diseases to at home hospitalization units and conventional hospitalization units will be measured with IMPROVE-Bleeding score (high or low risk). "IMPROVE-Bleeding" score is a risk assessment model that scores from 0 to 33, with a score of 7 or higher identifying patients at "high risk" of hemorrhagic events.

    Time frame: Within 3 months after hospitalization

  4. Incidence of thrombotic events

    Incidence of thrombotic events (deep venous thrombosis and pulmonary embolism) of patients admitted with acute medical diseases to at home hospitalization units and conventional hospitalization units

    Time frame: Within 3 months after hospitalization

  5. Incidence of atrial fibrillation diagnosis

    Incidence of atrial fibrillation diagnosis in patients admitted with acute medical diseases to at home hospitalization units and conventional hospitalization units

    Time frame: Within 3 months after hospitalization

  6. Accelerometry

    A GENEActiv watch will be used on left wrist at a sampling rate of 85,70 Hz to measure movement in the x, y, and z direction. The results will be the duration of sleep, the time spent in sedentary attitudes and the amount of light, moderate and vigorous physical activity. All the outcomes may range from 1 to 1440 minutes per day.

    Time frame: The duration of the hospitalization, from 0,9 days to 9 days

Secondary outcomes

  1. Prevalence of reduced mobility, measured with self-perceived immobilization

    Self-perceived immobilization evaluated at admission with Padua score. "Padua" score is a risk assessment model that scores from 0 to 20, with a score of 4 or higher identifying patients at "high risk" of thromboembolic disease, and in which "reduced mobility" scores 3 points.

    Time frame: Baseline

  2. Prevalence of reduced mobility, measured with accelerometry

    Reduced mobility will be assessed in an objective determination with a GENEActiv watch. A GENEActive watch will be used on left wrist at a sampling rate of 85,70 Hz to measure movement in the x, y, and z direction. The results will be the duration of sleep, the time spent in sedentary attitudes and the amount of light, moderate and vigorous physical activity. All the outcomes may range from 1 to 1440 minutes per day.

    Time frame: The duration of the hospitalization, from 0,9 days to 9 days

  3. Concordance of self-perceived immobilization and objective accelerometry measurements of physical activity for reduced mobility identification

    Reduced mobility can be assessed by subjective (e.g. self-perceived immobilization) or objective means (accelerometry). This outcome will determine the variability in identifying reduced mobility patients, when comparing reduced mobility assessed by subjective (self-perceived immobilization) or objective means (accelerometry)

    Time frame: At admission and during the duration of the hospitalization, from 0,9 days to 9 days

  4. International Physical Activity Questionnaire (IPAQ)

    The IPAQ is a validated 7-day recall questionnaire measuring current levels of physical activity. This questionnaire will be administered to participants aged under 65 years old. Scoring of the IPAQ results in a continuous variable in the form of total METs per week, which may be converted to METs per day. Higher scores means higher physical activity level. Additionally, walking, moderate physical activity and intense physical activity will be calculated as minutes per week. In addition, we will measure the change in physical activity levels from before hospitalization to three months later.

    Time frame: First day of hospitalization and 3 months after hospitalization

  5. The Spanish Short Version of the Minnesota Leisure Time Physical Activity Questionnaire (VREM)

    The VREM is a 6-item questionnaire that measures leisure time physical activity. It will be administered to people over 65 years of age. It reports energy expenditure over the past month expressed as 14-day METs. The number of METs per day will also be indicated. In addition, we will measure the change in physical activity levels from before hospitalization to three months later.

    Time frame: First day of hospitalization and 3 months after hospitalization

  6. Handgrip strength

    Muscle strength will be measured with a dynamometer and will be expressed in Kgs.

    Time frame: First (baseline) and last day of hospitalization (up to 9 days)

  7. 30-second sit-to-stand test

    Participants under 65 years of age will repeat as many of the sit-to-stand actions as possible in 30 seconds and the maximum number completed will be recorded.

    Time frame: First (baseline) and last day of hospitalization (up to 9 days)

  8. The Short Physical Performance Battery (SPPB)

    Participants over the age of 65 will complete the SPPB, which consists of 3 tests: 1) a progressive test of standing balance, 2) a 4-meter usual pace walk, and 3) a five-repetition chair stand test. Each test has a minimum score of 0 points and a maximum of 4 points. Thus, the final SPPB score ranges from 0 to 12 points.

    Time frame: First (baseline) and last day of hospitalization (up to 9 days)

  9. The Spanish Version of 5-level European Quality of Life-5 Dimensions (5-level EQ-5D)

    The 5-level EQ-5D (EQ-5D-5L) is a generic standardized instrument that will be used to describe and assess the health-related quality of life of people over 65 years of age. The 5-level EQ-5D (EQ-5D-5L) instrument consists of two parts: the EQ-5D descriptive system and the Visual Analogue Scale (VAS). The EQ-5D descriptive system comprises five dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. In the VAS, the individual scores his or her health between two extremes, 0 being the worst imaginable state of health and 100 the best imaginable state of health.

    Time frame: First day of hospitalization (baseline)

  10. Fried frailty criteria

    Frailty in people older than 65 years will be assessed according to five criteria: unintentional weight loss, low mood, gait speed, level of physical activity and muscle weakness. The stages of frailty have been defined as follows: a score of 0 means that a person is robust or not frail, a score of 1 or 2 indicates a risk for adverse outcomes and is considered to pre-frailty and a score of 3-5 suggests that the person is frail.

    Time frame: First day of hospitalization (baseline)

  11. Lobo's cognitive mini-examination

    This questionnaire examines several cognitive dimensions: temporal orientation, spatial orientation, attention, concentration and calculation, memory and language and construction. In people over 65 years of age, scores of 23-24 are the cut-off point at which a diagnosis of dementia is established. A score between 20 and 24 indicates mild cognitive impairment. Values between 15 and 19 represent moderate cognitive impairment and a clear sign of the existence of dementia. Finally, a score below 15 points suggests severe cognitive impairment leading to advanced dementia.

    Time frame: First day of hospitalization (baseline)

  12. Prevalence of pharmacological thromboprophylaxis use

    Prevalence of pharmacological thromboprophylaxis (low molecular weight heparin) use during admission

    Time frame: Last day of hospitalization (up to 9 days)

  13. Prevalence of correct pharmacological thromboprophylaxis use according to risk assessment models

    Prevalence of correct pharmacological thromboprophylaxis (low molecular weight heparin) use during admission, evaluated according to Padua and IMPROVE-VTE score

    Time frame: Last day of hospitalization (up to 9 days)

  14. Prevalence of correct pharmacological thromboprophylaxis use according to objective mobility evaluation with accelerometry

    Prevalence of correct pharmacological thromboprophylaxis (low molecular weight heparin) use during admission, evaluated according to Padua and IMPROVE-VTE score when mobility is evaluated objectively with accelerometry

    Time frame: Last day of hospitalization (up to 9 days)

07

Study locations

1 of 1 sites recruiting
  • Hospital Universitario de Navarra
    Pamplona, Navarra 31008, Spain
    Recruiting
    • Joao Modesto dos Santos, Medical Doctor · Contact0034689208762
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2023 (actual). Primary completion is estimated for Jan 2025, 22 months after the start.

Of 97 non-industry observational studies under Venous Thromboembolism, half reached primary completion within 46 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 86. This study's planned 22 months is below that.

Counting every sponsor, half of 118 studies reached it within 45 months; a quarter within 23 and three quarters within 75.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 31, 2023
First posted
Nov 1, 2023
StartActual
Mar 1, 2023
Primary completionEst.
Jan 31, 2025
CompletionEst.
Mar 2025
Last update
May 8, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 8, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06110949
Lead sponsor
Universidad Pública de Navarra
Collaborators
Sociedad Española De Medicina Interna, Daiichi Sankyo
Responsible party
Sponsor
First posted
Nov 1, 2023
Start date
Mar 1, 2023
Primary completion
Jan 31, 2025 (estimated)
Completion
Mar 2025 (estimated)
Last update
May 8, 2024

Study contacts

Joao Modesto dos Santos, Medical Doctor
Contact
jmodestosantos@gmail.com
0034689208762
Joao Modesto dos Santos, Medical Doctor
principal investigator · Hospital Universitario de Navarra, Spain

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion